Sotio Starts Phase 1/2 Trial of DCVAC/PCa plus ONCOS-102 in Advanced Prostate Cancer

Sotio Starts Phase 1/2 Trial of DCVAC/PCa plus ONCOS-102 in Advanced Prostate Cancer
The first patient has enrolled in Sotio‘s Phase 1/2 clinical trial testing the immunotherapy DCVAC/PCa in combination with ONCOS-102 in men with advanced prostate cancer. The patient was enrolled in Prague, Czech Republic. According to Sotio, this is the first trial of a combination of cellular immunotherapy and viral therapy conducted by a company from Central

Knowledge is power when living with prostate cancer.

Get access to the web’s leading Prostate Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

One comment

Leave a Comment

Your email address will not be published. Required fields are marked *